EGFR and cancer: Furthermore, there were no significant differences in mean and median HA scores based on pathologic grade (Kruskal-Wallis test, p = 0.9559), race (p = 0.7143), KRAS status (p = 0.6019), EGFR status (p = 0.3349), family history of cancer (p = 0.3881), ECOG PS (p = 0.4955), HA biopsy site (p = 0.514), and line of therapy at time of biopsy (p = 0.3229, Table 3).